What is the share price of Jagsonpal Pharmaceuticals Ltd (JAGSNPHARM) today?
The share price of JAGSNPHARM as on 5th December 2025 is ₹208.38. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Jagsonpal Pharmaceuticals Ltd (JAGSNPHARM) share?
The past returns of Jagsonpal Pharmaceuticals Ltd (JAGSNPHARM) share are- Past 1 week: 6.69%
- Past 1 month: -0.07%
- Past 3 months: -13.29%
- Past 6 months: -10.88%
- Past 1 year: -25.56%
- Past 3 years: 55.69%
- Past 5 years: 621.54%
What are the peers or stocks similar to Jagsonpal Pharmaceuticals Ltd (JAGSNPHARM)?
The peers or stocks similar to Jagsonpal Pharmaceuticals Ltd (JAGSNPHARM) include:What is the dividend yield % of Jagsonpal Pharmaceuticals Ltd (JAGSNPHARM) share?
The current dividend yield of Jagsonpal Pharmaceuticals Ltd (JAGSNPHARM) is 1.19.What is the market cap of Jagsonpal Pharmaceuticals Ltd (JAGSNPHARM) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Jagsonpal Pharmaceuticals Ltd (JAGSNPHARM) is ₹1391.59 Cr as of 5th December 2025.What is the 52 week high and low of Jagsonpal Pharmaceuticals Ltd (JAGSNPHARM) share?
The 52-week high of Jagsonpal Pharmaceuticals Ltd (JAGSNPHARM) is ₹301.65 and the 52-week low is ₹192.85.What is the PE and PB ratio of Jagsonpal Pharmaceuticals Ltd (JAGSNPHARM) stock?
The P/E (price-to-earnings) ratio of Jagsonpal Pharmaceuticals Ltd (JAGSNPHARM) is 25.13. The P/B (price-to-book) ratio is 5.80.Which sector does Jagsonpal Pharmaceuticals Ltd (JAGSNPHARM) belong to?
Jagsonpal Pharmaceuticals Ltd (JAGSNPHARM) belongs to the Health Care sector & Pharmaceuticals sub-sector.How to buy Jagsonpal Pharmaceuticals Ltd (JAGSNPHARM) shares?
You can directly buy Jagsonpal Pharmaceuticals Ltd (JAGSNPHARM) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Jagsonpal Pharmaceuticals Ltd
JAGSNPHARM Share Price
208.384.45% (-9.71)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
JAGSNPHARM Stock Scorecard
Performance
AvgPrice return has been average, nothing exciting
Valuation
HighSeems to be overvalued vs the market average
Growth
AvgFinancials growth has been moderate for a few years
Profitability
HighShowing good signs of profitability & efficiency
Entry point
GoodThe stock is underpriced and is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
JAGSNPHARM Performance & Key Metrics
JAGSNPHARM Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 22.47 | 5.80 | 1.19% |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 36.87 | 5.82 | 0.59% |
JAGSNPHARM Analyst Ratings & Forecast
—
Analyst Ratings data is currently unavailable for this stockPrice Upside
Earnings Growth
Rev. Growth
JAGSNPHARM Company Profile
Jagsonpal Pharmaceuticals Limited is engaged in pharmaceutical business. It specializes in developing and manufacturing bulk drugs and pharmaceutical formulations.
SUNPHARMA
PE Ratio
39.63
39.63
1Y Return
0.45%
0.45%
Buy Reco %
91.67
91.67
TORNTPHARM
PE Ratio
67.04
67.04
1Y Return
12.63%
12.63%
Buy Reco %
76.92
76.92
CIPLA
PE Ratio
23.30
23.30
1Y Return
1.51%
1.51%
Buy Reco %
70.00
70.00
DRREDDY
PE Ratio
18.77
18.77
1Y Return
2.85%
2.85%
Buy Reco %
41.94
41.94
LUPIN
PE Ratio
29.21
29.21
1Y Return
1.24%
1.24%
Buy Reco %
72.22
72.22
JAGSNPHARM Sentiment Analysis
JAGSNPHARM Sentiment Analysis
New
Crisp summary & key insights to decode earnings calls instantly
JAGSNPHARM Stock Summary · November 2025
In Q2 FY26, the company demonstrated resilience with a 10% sales increase and a 39% rise in profit after tax, despite challenges from the GST transition and logistical disruptions. While maintaining a strong cash position of INR 160.4 crores, the focus on operational efficiency and strategic product launches is crucial for enhancing profitability and market positioning. The management is optimistic about future growth, particularly in women's health and through the integration of acquired businesses, although the decline in key product revenues underscores the need for a balanced approach to brand management. With a commitment to improving Return on Capital Employed and addressing workforce challenges, the company aims to navigate its growth trajectory effectively.
JAGSNPHARM Stock Growth Drivers
JAGSNPHARM Stock Growth Drivers
8Strong Financial Performance
Jagsonpal Pharmaceuticals Limited has reported a 10% increase in sales and a 39% rise in
Successful Acquisition Integration
The acquisition of Yash Pharma has been successfully managed, with the business now recognized as
JAGSNPHARM Stock Challenges
JAGSNPHARM Stock Challenges
6Decline in Intangible Assets
The company reported a decline in intangible assets from Rs. 89 crores to Rs. 81
Underperformance of Key Product
The product Dydrogesterone has seen a significant revenue decline from Rs. 40 crores to Rs.
JAGSNPHARM Forecast
JAGSNPHARM Forecasts
Forecast data is currently unavailable
Forecast data is currently unavailable
Price
Price Upside
Revenue
Revenue Growth
Earnings
Earnings Per Share
JAGSNPHARM
JAGSNPHARM
Income
Balance Sheet
Cash Flow
Annual Normal View
JAGSNPHARM Income Statement
JAGSNPHARM Income Statement
Annual Normal View
| Financial Year | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 157.14 | 126.99 | 168.26 | 161.10 | 192.34 | 221.01 | 242.44 | 217.98 | 300.27 | 316.79 | ||||||||||
Raw Materials | 67.34 | 65.19 | 53.43 | 54.94 | 75.50 | 83.35 | 88.04 | 76.08 | 98.56 | 227.68 | ||||||||||
| Power & Fuel Cost | 2.12 | 1.00 | 1.41 | 0.64 | 0.52 | 0.47 | 0.29 | 0.17 | 0.19 | |||||||||||
| Employee Cost | 40.95 | 41.88 | 46.61 | 50.37 | 53.98 | 57.68 | 65.18 | 62.09 | 70.93 | |||||||||||
| Selling & Administrative Expenses | 30.19 | 27.56 | 32.23 | 38.34 | 31.88 | 42.50 | 41.66 | 40.80 | 48.54 | |||||||||||
| Operating & Other expenses | -2.50 | 2.01 | 23.81 | 5.75 | 6.99 | 8.56 | 10.85 | 6.50 | 3.09 | |||||||||||
EBITDA | 19.04 | -10.65 | 10.77 | 11.06 | 23.47 | 28.45 | 36.42 | 32.34 | 78.96 | 89.11 | ||||||||||
| Depreciation/Amortization | 1.99 | 0.32 | 1.02 | 1.13 | 1.09 | 1.53 | 1.21 | 1.66 | 8.13 | 9.46 | ||||||||||
| PBIT | 17.05 | -10.97 | 9.75 | 9.93 | 22.38 | 26.92 | 35.21 | 30.68 | 70.83 | 79.65 | ||||||||||
| Interest & Other Items | 2.64 | 0.66 | 0.75 | 0.51 | 0.51 | 0.29 | 0.41 | 0.81 | 0.96 | 1.04 | ||||||||||
| PBT | 14.41 | -11.63 | 9.00 | 9.42 | 21.87 | 26.63 | 34.80 | 29.87 | 69.87 | 78.61 | ||||||||||
| Taxes & Other Items | 2.53 | -0.08 | 1.78 | 1.54 | 4.82 | 7.78 | 8.09 | 7.41 | 14.50 | 16.69 | ||||||||||
| Net Income | 11.88 | -11.55 | 7.22 | 7.88 | 17.05 | 18.85 | 26.71 | 22.46 | 55.37 | 61.92 | ||||||||||
| EPS | 1.81 | -1.76 | 1.10 | 1.20 | 2.60 | 2.88 | 4.08 | 3.41 | 8.36 | 9.33 | ||||||||||
| DPS | 0.04 | 0.04 | 0.10 | 0.20 | 0.40 | 1.60 | 2.00 | 2.00 | 2.50 | 2.50 | ||||||||||
| Payout ratio | 0.02 | — | 0.09 | 0.17 | 0.15 | 0.56 | 0.49 | 0.59 | 0.30 | 0.27 |
JAGSNPHARM Company Updates
FY 2026FY 2026
Investor Presentation
Nov 3PDF
Jul 26PDF
JAGSNPHARM Stock Peers
JAGSNPHARM Past Performance & Peer Comparison
JAGSNPHARM Past Performance & Peer Comparison
Comparing 3 stocks from
Health CarePharmaceuticals
Compare valuation on Screener
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Jagsonpal Pharmaceuticals Ltd | 25.13 | 5.80 | 1.19% |
| Sun Pharmaceutical Industries Ltd | 39.63 | 5.98 | 0.89% |
| Torrent Pharmaceuticals Ltd | 67.04 | 16.88 | 0.85% |
| Cipla Ltd | 23.30 | 3.93 | 1.05% |
JAGSNPHARM Stock Price Comparison
Compare JAGSNPHARM with any stock or ETFCompare JAGSNPHARM with any stock or ETF
JAGSNPHARM
JAGSNPHARM Holdings
JAGSNPHARM Shareholdings
JAGSNPHARM Promoter Holdings Trend
JAGSNPHARM Promoter Holdings Trend
Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
JAGSNPHARM Institutional Holdings Trend
JAGSNPHARM Institutional Holdings Trend
Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has almost stayed constant
JAGSNPHARM Shareholding Pattern
JAGSNPHARM Shareholding Pattern
JAGSNPHARM Shareholding History
JAGSNPHARM Shareholding History
Foreign Institutions
Mutual Funds Invested in JAGSNPHARM
Mutual Funds Invested in JAGSNPHARM
No mutual funds holding trends are available
Top 1 Mutual Funds holding Jagsonpal Pharmaceuticals Ltd
| Funds (Top 1) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
|---|---|---|---|---|
The rupee value of the stock held by the fund divided by the stock’s market cap 0.0004% | Percentage of the fund’s portfolio invested in the stock 0.03% | Change in the portfolio weight of the stock over the last 3 months 0.03% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 110/124 (+5) |
Compare 3-month MF holding change on Screener
smallcases containing JAGSNPHARM stock
smallcases containing JAGSNPHARM stock
Looks like this stock is not in any smallcase yet.
JAGSNPHARM Events
JAGSNPHARM Events
JAGSNPHARM Dividend Trend
No Dividend Cuts
Dividends are the portion of earnings that a company distributes to all its shareholders every year
JAGSNPHARM has increased or maintained dividend levels over the last 5 years
Dividend Yield
Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation
Current dividend yield is 1.19%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹11.93 every year
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
JAGSNPHARM Dividend Trend
No Dividend Cuts
Dividends are the portion of earnings that a company distributes to all its shareholders every year
JAGSNPHARM has increased or maintained dividend levels over the last 5 years
Dividend Yield
Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation
Current dividend yield is 1.19%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹11.93 every year
JAGSNPHARM Upcoming Dividends
JAGSNPHARM Upcoming Dividends
No upcoming dividends are available
JAGSNPHARM Past Dividends
JAGSNPHARM Past Dividends
Cash Dividend
Ex DateEx DateSep 12, 2025
Final
Final | Div/Share: ₹2.50
Dividend/Share
₹2.50
Ex DateEx Date
Sep 12, 2025
Cash Dividend
Ex DateEx DateSep 6, 2024
Final
Final | Div/Share: ₹5.00
Dividend/Share
₹5.00
Ex DateEx Date
Sep 6, 2024
Cash Dividend
Ex DateEx DateAug 21, 2023
Final
Final | Div/Share: ₹5.00
Dividend/Share
₹5.00
Ex DateEx Date
Aug 21, 2023
Cash Dividend
Ex DateEx DateOct 29, 2021
Interim
Interim | Div/Share: ₹4.00
Dividend/Share
₹4.00
Ex DateEx Date
Oct 29, 2021
Cash Dividend
Ex DateEx DateSep 22, 2021
Final
Final | Div/Share: ₹1.00
Dividend/Share
₹1.00
Ex DateEx Date
Sep 22, 2021
JAGSNPHARM Stock News & Opinions
JAGSNPHARM Stock News & Opinions
Articles & Videos
Hmm, looks like data is unavailable here. Please come back after some time.
Over the last 5 years, revenue has grown at a yearly rate of 13.26%, vs industry avg of 10.04%
Over the last 5 years, market share increased from 0.06% to 0.07%
Over the last 5 years, net income has grown at a yearly rate of 47.69%, vs industry avg of 20.02%